

Date: September 05, 2026

To The Manager, Listing Department, National Stock Exchange of India Limited, (NSE) Exchange Plaza, C-1, Block-G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.	To The Manager, The Department of Corporate Service, BSE Limited, (BSE) 25 th Floor, Phiroze Jeejeebhoy Tower, Dalal Street, Fort, Mumbai – 400 001.
Scrip Code – LINCOLN	Scrip Code – 531633

Dear Sir / Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

Pursuant to Regulation 30 and in compliance with Regulation 36(1)(b) of the SEBI Listing Regulations, we hereby inform you that letter(s) providing a web-link and the exact path of Company's website to access the Notice and Annual Report for the Financial Year 2025-26 is being sent to the shareholders, whose email addresses are not registered with the Company/ Registrar and Share Transfer Agent/ depositories/ depositories participants.

A copy of the letter is enclosed for your record.

The above information is also available on the Company's website at <https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/annual-report/#1676612189181-623364ff-dabe>.

You are requested to take the above on your records.

Thanking you,

Yours faithfully,

For Lincoln Pharmaceuticals Limited

Trusha Shah
Company Secretary &
Compliance Officer

Encl: a/a

Regd. Office : "Lincoln House", Science City Road, Sola, Ahmedabad-380 060. Gujarat, India
Phone : +91-79-4107 8000 | **Fax :** +91-79-4107 8062 | **CIN** L24230GJ1995PLC024288
E-mail : info@lincolnpharma.com | **Website :** www.lincolnpharma.com

Factory : 10, 12, 13, Trimul Estate, Near Khatraj Chokadi, P.O. Khatraj-382721.

Ta. : Kalol, Dist. Gandhinagar, (Guj.) | **Phone :** +91-79-49135000 | **E-mail :** khatraj@lincolnpharma.com





LINCOLN PHARMACEUTICALS LIMITED

CIN: L24230GJ1995PLC024288

Regd. Office: "LINCOLN HOUSE", Behind Satyam Complex,
Science City Road, Sola, Ahmedabad – 380 060, Gujarat, India.

Ph: 079-41078000; E-Mail: investor@lincolnpharma.com; Website: www.lincolnpharma.com

Date: 5th September, 2026

Sub.: Notice of 32nd Annual General Meeting (AGM) of Lincoln Pharmaceuticals Limited and Annual Report for the Financial Year 2025-26.

Dear Shareholder(s),

We are pleased to inform you that the **32nd Annual General Meeting ('AGM')** of the members of **Lincoln Pharmaceuticals Limited** is scheduled to be held on **Wednesday, 30th September, 2026 at 11:00 A.M. (IST)** through **Video Conferencing ('VC') facility / Other Audio-Visual Means ('OAVM')**.

As per Regulation 36(1)(b) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('SEBI Listing Regulations, 2015') as amended, the web-link, including the exact path, where complete details of the Integrated Annual Report are available is required to be sent to those member(s) who have not registered their email address(es) either with the Company or with any Depository or MUFG Intime India Private Limited (Formerly Link Intime India Private Limited), Registrar & Share Transfer Agent (**RTA**) of the Company.

Accordingly, the web-link, including the exact path where complete details of the Annual Report for the Financial Year 2025-26 are available at:

Website: www.lincolnpharma.com

Weblink: <https://www.lincolnpharma.com/investor/disclosures-under-regulation-46-of-the-lodr/annual-report/>

Exact path of Annual Report 2025-26: www.lincolnpharma.com >> Investors >> Disclosures under Regulation 46 of the LODR >> Point-17: Annual Reports >> 2025-26

This letter is being sent to those member(s) who have not registered their email address(es) either with the Company or with any Depository or RTA of the Company as on the cut-off date as on August 28, 2026.

This is also a reminder to update KYC details pursuant to SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 7, 2024, and to dematerialize physical securities.

The circular issued by SEBI mandates all the listed companies to record PAN, Address with PIN code, Mobile Number, Bank Account details, Specimen Signature and choice of Nomination of security holders holding securities in physical mode. While updating Email ID is optional, the security holders are requested to register email id also to avail online services. This is applicable for all security holders holding securities in physical mode.

The formats for choice of Nomination and Updation of KYC details viz; Forms ISR-1, ISR-2, ISR-3, SH-13, SH-14 and SEBI circulars are available on our website as mentioned below:

<https://www.in.mpms.mufg.com> >Resources > Downloads > KYC > Formats for KYC.\

The aforesaid SEBI Circular also mandates that security holders holding in physical mode whose folios do not have PAN, Choice of Nomination, Contact details, Bank Account details and Specimen Signature updated, shall be eligible for any payment including dividend, interest or redemption payment in respect of such folios, only through electronic mode with effect from April 1, 2024.

All Shareholder queries or service requests in electronic mode are to be raised only through our website, the link for which is https://web.in.mpms.mufg.com/helpdesk/Service_Request.html or +918108116767.

Moreover, you are also requested to update your email address at the earliest either through your depository participants for electronic holding or send a communication to us / our RTA to facilitate the updation to continue receiving all important information & documents thereafter and encourage Green Initiative.

Thanking you,

Yours faithfully,

For Lincoln Pharmaceuticals Limited,

Sd/-

Trusha Shah

Company Secretary and Compliance Officer

Membership No:A59416